These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 36000807)

  • 1. Epigenetic engineering for optimal chimeric antigen receptor T cell therapy.
    Ito Y; Kagoya Y
    Cancer Sci; 2022 Nov; 113(11):3664-3671. PubMed ID: 36000807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors.
    Ahn T; Bae EA; Seo H
    Mol Ther; 2024 Jun; 32(6):1617-1627. PubMed ID: 38582965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic strategies to boost CAR T cell therapy.
    Akbari B; Ghahri-Saremi N; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
    Mol Ther; 2021 Sep; 29(9):2640-2659. PubMed ID: 34365035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine signaling in chimeric antigen receptor T-cell therapy.
    Kagoya Y
    Int Immunol; 2024 Feb; 36(2):49-56. PubMed ID: 37591521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of next-generation chimeric antigen receptor-engineered T-cell therapy].
    Kagoya Y
    Rinsho Ketsueki; 2022; 63(9):1290-1297. PubMed ID: 36198555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it.
    Yin X; He L; Guo Z
    Immunology; 2023 Aug; 169(4):400-411. PubMed ID: 36942414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy.
    Bulliard Y; Andersson BS; Baysal MA; Damiano J; Tsimberidou AM
    J Hematol Oncol; 2023 Oct; 16(1):108. PubMed ID: 37880715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor T cell persistence and memory cell formation.
    McLellan AD; Ali Hosseini Rad SM
    Immunol Cell Biol; 2019 Aug; 97(7):664-674. PubMed ID: 31009109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells.
    You L; Han Q; Zhu L; Zhu Y; Bao C; Yang C; Lei W; Qian W
    Front Immunol; 2020; 11():1787. PubMed ID: 32973749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-Intrinsic Barriers of T Cell-Based Immunotherapy.
    Ghoneim HE; Zamora AE; Thomas PG; Youngblood BA
    Trends Mol Med; 2016 Dec; 22(12):1000-1011. PubMed ID: 27825667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and epigenetic orchestration of (CAR) T cell fate and function.
    Akbari B; Hosseini Z; Shahabinejad P; Ghassemi S; Mirzaei HR; O'Connor RS
    Cancer Lett; 2022 Dec; 550():215948. PubMed ID: 36209973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells.
    Grunewald CM; Haist C; König C; Petzsch P; Bister A; Nößner E; Wiek C; Scheckenbach K; Köhrer K; Niegisch G; Hanenberg H; Hoffmann MJ
    Front Immunol; 2021; 12():782448. PubMed ID: 34868059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
    Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
    Gumber D; Wang LD
    EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Sun C; Li D; Wang Z
    Immunotherapy; 2024 Mar; 16(5):331-340. PubMed ID: 38264838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.
    Marofi F; Rahman HS; Achmad MH; Sergeevna KN; Suksatan W; Abdelbasset WK; Mikhailova MV; Shomali N; Yazdanifar M; Hassanzadeh A; Ahmadi M; Motavalli R; Pathak Y; Izadi S; Jarahian M
    Front Immunol; 2021; 12():681984. PubMed ID: 34248965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.